Here is the New York Times article that Rocketman2 referenced.

Generic Crestor Wins Approval, Dealing a Blow to AstraZeneca

I don't think this has any effect whatsoever on RVX-208. Rosuvastatin/Crestor was already projected to be off patent by the time of Resverlogix filing, for RVX-208, a New Drug Application with the FDA or Marketing Authorization Appilcation with the EMA. Furthermore, Crestor was already expected to go off patent in 2016. AstraZeneca had a failed last ditch effort to avoid this.

BearDownAZ